Nuvation Bio INC Form 4 insider transactions

Philippe Sauvage, Chief Financial Officer of Nuvation Bio Inc., reported multiple transactions in common stock on July 15, 2026.

Nuvation Bio Inc. reports that Chief People Officer Stacy Markel sold a significant number of Class A common stock shares through a pre-arranged 10b5-1 trading plan.

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., sold 63,000 shares of Class A Common Stock for $2.93 per share under a pre-arranged 10b5-1 plan.

Nuvation Bio Inc. CFO Philippe Sauvage sold 47,668 shares of Class A Common Stock for an average price of $6.00, as part of a pre-arranged 10b5-1 trading plan.

Director Robert Mashal acquired 25,000 shares of Nuvation Bio Inc. (NUVB) at a price of $4.73 per share.

Nuvation Bio Inc. reports that Director Vernon W. Anthony acquired stock options for 123,397 shares of Class A Common Stock.

Nuvation Bio Inc. reports that Director Robert Mashal acquired stock options for 123,397 shares of Class A Common Stock.

Nuvation Bio Inc. reports that Director Kathryn E. Falberg acquired stock options on May 21, 2026, with an exercise price of $4.79.

Nuvation Bio Inc. reports a stock option grant to Director Kim D. Blickenstaff for 123,397 shares at an exercise price of $4.79, with vesting tied to service anniversaries or annual meetings.

Nuvation Bio Inc. reports that Director Robert B. Bazemore acquired stock options for 123,397 shares of Class A Common Stock.

Nuvation Bio Inc. reports that Director Xiangmin Cui acquired stock options for 123,397 shares of Class A Common Stock.

Nuvation Bio Inc. files an amended Form 4 to correct an administrative error in the reporting of stock options granted to Director Xiangmin Cui.

Chief Regulatory Officer Kerry Wentworth exercised options for 36,750 shares and subsequently sold them under a 10b5-1 plan.

Chief Medical Officer Dongfang Liu exercised options for 50,000 shares and subsequently sold them under a 10b5-1 trading plan.

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., reported transactions involving Class A Common Stock, including purchases and sales executed under a 10b5-1 plan.

Nuvation Bio Inc.'s Chief Medical Officer, Liu Dongfang, was granted 748,130 stock options with an exercise price of $5.91, vesting over four years.

Nuvation Bio Inc.'s VP of Finance, Moses Makunje, was granted 50,761 Restricted Stock Units and options to purchase 224,439 shares of Class A Common Stock.

Nuvation Bio's Chief Regulatory Officer, Kerry Wentworth, was granted 748,130 stock options and holds 53,000 shares of Class A Common Stock.

Nuvation Bio's Chief Commercial Officer, Colleen Sjogren, reported the grant of 748,130 stock options and beneficial ownership of 84,000 Class A Common Stock.

Nuvation Bio Inc.'s Chief Financial Officer, Philippe Sauvage, was granted 748,130 stock options with an exercise price of $5.91, vesting over four years.

Nuvation Bio's Chief People Officer, Stacy Markel, reported beneficial ownership of 32,591 Class A Common Stock shares and a new grant of 748,130 stock options.

Nuvation Bio Inc. Director Xiangmin Cui was granted 74,813 stock options with an exercise price of $5.91, vesting monthly over two years.

Nuvation Bio Inc.'s Chief Scientific Officer, Gary Hattersley, was granted 748,130 stock options with an exercise price of $5.91.

Nuvation Bio's Chief Technical Operations Officer, David C. Hanley, was granted 748,130 stock options with an exercise price of $5.91, vesting over four years.

Nuvation Bio Inc. President and CEO David Hung was granted 1,995,012 stock options with an exercise price of $5.91, vesting over four years.

Nuvation Bio Inc.'s Chief Medical Officer, Liu Dongfang, exercised stock options and subsequently sold 150,000 Class A Common Stock shares for a weighted-average price of $7.8217.

Nuvation Bio's Chief Medical Officer, Dongfang Liu, exercised stock options and subsequently sold a portion of Class A Common Stock in late November 2025.

Nuvation Bio's Chief Scientific Officer, Gary Hattersley, exercised stock options and subsequently sold a total of 369,051 Class A Common Stock shares.

Nuvation Bio's Chief Medical Officer, Liu Dongfang, exercised stock options and subsequently sold 20,000 shares of Class A Common Stock.

Nuvation Bio's Chief Technical Operations, David C. Hanley, exercised stock options and subsequently sold 200,000 Class A Common Stock shares.